Publication:
Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis

Loading...
Thumbnail Image
Date
2016-05-02
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Gonzalez Guerrero, Rebeca ; Martínez Barba, Enrique ; Piñero Madrona, Antonio ; Cabezas Herrera, Juan ; Montenegro Arce, María Fernanda ; Rodríguez López, José Neptuno ; Sánchez del Campo Ferrer, Luis
item.page.secondaryauthor
item.page.director
Publisher
Springer Nature
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1038/onc.2016.154
item.page.type
info:eu-repo/semantics/article
Description
© 2014, The authors. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Accepted version of a Published Work that appeared in final form in Oncogene. To access the final edited and published work see https://doi.org/10.1038/onc.2016.154
Abstract
During the course of cancer progression, neoplastic cells undergo dynamic and reversible transitions between multiple phenotypic states, and this plasticity is enabled by underlying shifts in epigenetic regulation. Our results identified a negative feedback loop in which SET9 controls DNA methyltransferase-1 protein stability, which represses the transcriptional activity of the SET9 promoter in coordination with Snail. The modulation of SET9 expression in breast cancer cells revealed a connection with E2F1 and the silencing of SET9 was sufficient to complete an epigenetic program that favored epithelial–mesenchymal transition and the generation of cancer stem cells, indicating that SET9 plays a role in modulating breast cancer metastasis. SET9 expression levels were significantly higher in samples from patients with pathological complete remission than in samples from patients with disease recurrence, which indicates that SET9 acts as a tumor suppressor in breast cancer and that its expression may serve as a prognostic marker for malignancy
Citation
Oncogene, 2016, Vol. 35, pp. 6143–6152
item.page.embargo
Collections